产品
编 号：F752289
分子式：C47H87N3O2
分子量：726.21
分子式：C47H87N3O2
分子量：726.21
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2412492-07-8
产品详情
生物活性：
A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma..
体内研究：
A2-Iso5-2DC18, loaded with mLuc or Cre-recombinase mRNA LNPs (mCre), (0.1 mg/kg and 0.5 mg/kg; s.c.; once a week, for 2 weeks) transfects central antigen presenting cells (APCs) in A14/Cre mRNA mouse model.A2-Iso5-2DC18 loaded with OVA mRNA (mOVA) vaccine, (15?μg mOVA per mouse; s.c.; twice dose, once every 5 d) induces a significantly high antigen-specific cytotoxic T lymphocyte (CTL) response, in parallel with robust IFN-? secretion in B16F10 mouse melanoma model.Animal Model:A14/Cre mRNA mouse model (female B6 mice)
Dosage:Loaded with Cre-recombinase mRNA LNPs (mCre); 0.1 mg/kg and 0.5 mg/kg
Administration:Subcutaneous injection; 3 weeks
Result:Induced protein expression in the local injection site and the draining lymph nodes and transfected central antigen presenting cells (APCs) including macrophages/monocytes (CD11b+) and dendritic cells (CD11c+) in mice.
Animal Model:Ovalbumin (OVA)-expressing B16F10 mouse melanoma model
Dosage:Loaded with OVA mRNA (mOVA) vaccine; 15?μg mOVA per mouse
Administration:Subcutaneous injection; once per week for the first two weeks; 3 weeks continuous observation
Result:Significantly decreased tumor volume of B16-OVA melanoma and improved overall survival in mice.Increased the number of systemic and tumor-infiltrating antigen-specific T?cells dramatically (20–30-fold).
A2-Iso5-2DC18 is a dihydroimidazole-linked lipid, served as potent mRNA delivery vehicle. A2-Iso5-2DC18 can be used for antitumor research, including B16F10 melanoma..
体内研究：
A2-Iso5-2DC18, loaded with mLuc or Cre-recombinase mRNA LNPs (mCre), (0.1 mg/kg and 0.5 mg/kg; s.c.; once a week, for 2 weeks) transfects central antigen presenting cells (APCs) in A14/Cre mRNA mouse model.A2-Iso5-2DC18 loaded with OVA mRNA (mOVA) vaccine, (15?μg mOVA per mouse; s.c.; twice dose, once every 5 d) induces a significantly high antigen-specific cytotoxic T lymphocyte (CTL) response, in parallel with robust IFN-? secretion in B16F10 mouse melanoma model.Animal Model:A14/Cre mRNA mouse model (female B6 mice)
Dosage:Loaded with Cre-recombinase mRNA LNPs (mCre); 0.1 mg/kg and 0.5 mg/kg
Administration:Subcutaneous injection; 3 weeks
Result:Induced protein expression in the local injection site and the draining lymph nodes and transfected central antigen presenting cells (APCs) including macrophages/monocytes (CD11b+) and dendritic cells (CD11c+) in mice.
Animal Model:Ovalbumin (OVA)-expressing B16F10 mouse melanoma model
Dosage:Loaded with OVA mRNA (mOVA) vaccine; 15?μg mOVA per mouse
Administration:Subcutaneous injection; once per week for the first two weeks; 3 weeks continuous observation
Result:Significantly decreased tumor volume of B16-OVA melanoma and improved overall survival in mice.Increased the number of systemic and tumor-infiltrating antigen-specific T?cells dramatically (20–30-fold).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备